References
- Åhrén T., Lithell H., Vessby B., Victor A., Johansson E. D. B. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. I. Carbohydrate metabolism and liver function. Contraception 1981; 24: 415–427
- Åhrén T., Lithell H., Victor A., Vessby B., Johansson E. D. B. Serum lipoprotein and apolipoprotein changes during treatment with a contraceptive vaginal ring containing levonorgestrel and estradiol. Contraception 1981; 24: 451–468
- Bradley D. D., Wingerd J., Petitti D. B., Krauss R. M., Ramcharan S. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med 1978; 299: 17–20
- Coutinho E. M., Da Silva A. R., Kraft H. G. Fertility control with subdermal silastic capsules containing a new progestin (ST-1435). Int J Fertil 1976; 21: 103–108
- Croxatto H. B., Diaz S., Robertson D. N., Pavez M. Clinical chemistry in women treated with levonorgestrel implants (NORPLANT) and a TCu 200 IUD. Contraception 1983; 27: 281–288
- Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B., Dawber T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977; 62: 707–714
- Hammond G. L., Lähteenmäki P. L. A., Lähteenmäki P., Luukkainen T. Distribution and percentages of non-protein bound contraceptive steroids in human serum. J Steroid Biochem 1982; 17: 375–380
- Havekes L., van Gent C. M., Stegerhoek C. I., Arntzenius A. C., Hessel L. W. High density lipoprotein cholesterol and apolipoprotein A-I levels in 32–33-year-old women on steroid contraceptives – differences between two frequently used low-estrogen pills. Clin Chim Acta 1981; 116: 223–229
- Larsson-Cohn U., Fåhraeus L., Wallentin L., Zador G. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril 1981; 35: 172–179
- Lähteenmäki P. L. A., Weiner E., Lähteenmäki P., Johansson E. D. B., Luukkainen T. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST 1435. Contraception 1982; 25: 299–306
- Lithell H., Åhrén T., Odlind V., Weiner E., Vessby B., Victor A., Johansson E. D. B. Effects of progestins on lipoprotein patterns. Progesterone and Progestins, C. W. Bardin, E. Milgröm, P. Mauvais-Jarvis. Raven Press, New York 1983; 421–432
- Odlind V., Lithell H., Kurunmäki H., Lähteenmäki P., Toivonen J., Luukkainen T., Johansson E DB. ST-1435: Development of an implant. Long-acting Contraceptive Delivery Systems, G. I. Zatuchni, A. Goldsmidt, J. D. Shelton, J. J. Sciarra, 1984, In press
- Rhoads G. G., Gulbrandsen C. L., Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976; 294: 293–298
- Robertson D. N., Sivin I., Nash H. A., Braun J., Dinh J. Release rates of levonorgestrel from Silastic capsules, homogenous rods and covered rods in humans. Contraception 1983; 27: 483–495
- Slone D., Shapiro S., Kaufman D. W., Rosenberg L., Miettinen O. S., Stolley P. D. Risk of myocardial infarction in current and discontinued use of oral contraceptives. N Engl J Med 1981; 305: 420–424
- Spellacy W. N., Buhi W. C., Birk S. A. The effects of norgestrel on carbohydrate and lipid metabolism over one year. Am J Obstet Gynecol 1976; 125: 984–986
- Vessby B., Boberg J., Gustafsson I. B., Karlström B., Lithell H., Östlund-Lindqvist A. M. Reduction of high density lipoprotein cholesterol and apolipoprotein A-I concentrations by a lipid-lowering diet. Atherosclerosis 1980; 35: 21–27